At Xylyx Bio, we have developed human derived, disease-specific ECM cell culture substrates as 2D and 3D cell-based assays for anti-fibrotic drug discovery. Our disease-specific ECM products are applicable across multiple stages of the early-stage drug discovery pipeline, from target selection and hit identification through lead identification and optimization.
Read press release
Accelerate and improve drug discovery and screening in IPF with custom IPF-specific ECM substrates, allowing drug candidates to be studies in a human, disease-relevant environment in vitro.
Implement custom NASH-derived ECM substrates into preclinical human disease models and cell-based screening assays to increase clinical relevance and success rates.